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Abstract
Background:  Nuclear localization of proteolytically formed intracellular fragment of ErbB4
receptor tyrosine kinase has been shown to promote cell survival, and nuclear localization of ErbB4
receptor has been described in human breast cancer. Tumor necrosis factor alpha converting
enzyme (TACE) initiates the proteolytic cascade leading to ErbB4 intracellular domain formation.
Interactions between matrix metalloproteases and heparan sulfate have been described, but the
effect of cell surface heparan sulfate on TACE activity has not been previously described.
Results: As indicated by immunodetection of increased ErbB4 intracellular domain formation and
direct enzyme activity analysis, TACE activity was substantially amplified by enzymatic removal of
cell surface heparan sulfate but not chondroitin sulfate.
Conclusion: In this communication, we suggest a novel role for cell surface heparan sulfate.
Removal of cell surface heparan sulfate led to increased formation of ErbB4 intracellular domain.
As ErbB4 intracellular domain has previously been shown to promote cell survival this finding may
indicate a novel mechanism how HS degradation active in tumor tissue may favor cell survival.
Background
Heparan sulfate (HS) is a sulfated polysaccharide which
consists of glucosamine and glucuronic or iduronic acid
disaccharide units. Several HS chains are attached to a syn-
decan or glypican protein core. HS has been found to bind
and regulate the activity of various extracellular matrix
metalloproteases (MMP) such as MMP-1, MMP-2, MMP-
7, MMP-9 and MMP-13 [1]. In Alzheimer's disease the
activity of BACE1, an enzyme responsible for the produc-
tion of the amyloidogenic peptide, has been shown to be
directly regulated by interactions with HS [2].
Cell surface proteases take part in cell signaling by i) pro-
ducing soluble extracellular mediators such as growth fac-
tors, chemokines and cytokines from membrane bound
precursors [3] and ii) generating intracellular signaling
molecules from transmembrane protein receptors [4,5].
One such cell surface protease is tumor necrosis factor
alpha (TNF-α) converting enzyme, TACE [3].
TACE has also been shown to cleave various cell surface
receptors including ErbB4 [6]. ErbB4 receptor belongs to
the EGF receptor family of receptor tyrosine kinases
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(RTKs), which share homology with the avian erythrob-
lastosis virus oncogenic factor v-erbB. It has been shown
to stimulate cell survival, proliferation and differentiation
[7,8].
Four different ErbB4 isoforms can be generated by alterna-
tive splicing [9,10]. The juxtamembrane isoform JM-a is
recognized and cleaved by TACE, whereas JM-b is not
cleavable [9]. The cytoplasmic isoforms either bind (JM-a
CYT-1, JM-b CYT-1) or can not bind (JM-a CYT-2, JM-b
CYT-2 phosphoinositide 3-kinase (PI 3-K) [10]. Proteolyt-
ically produced ErbB4 CYT-2 80 kDa fragments has been
shown to favor cell survival [8].
The expression of heparan sulfate cleaving β-endoglu-
curonidase, heparanase, is tightly controlled in normal
tissues [11,12]. However, in inflammed or cancer tissue
and in several cancer cell lines the expression of hepara-
nase has been shown to be elevated [13-15] and the high
expression of heparanase has been linked to highly inva-
sive cancers [15-17]. In breast cancer nuclear localization
of ErbB4 receptor has been demonstrated and nuclear
ErbB4 expression has been shown to be associated with
unfavorable disease prognosis when compared to mem-
braneous ErbB4 expression [18].
In this communication we describe for the first time that
removal of cell surface HS increases membrane bound
ErbB4 80 kDa fragment formation by TACE-like activity.
Further, removal of cell surface HS enhanced the capabil-
ity of living cells to cleave synthetic TACE substrate pep-
tide suggesting that cell surface HS regulates TACE activity.
Methods
Preparation of expression constructs
Hemagglutinin (HA) -tagged human TACE encoding vec-
tor [19] was a generous gift from Professor A. Ullrich, Max
Planck Institute, Germany. HA-tagged ErbB4 JM-a and JM-
b CYT-2 receptor constructs were generated as follows:
Sequence encoding the aminoterminal part of the full
length receptor [8] was joined in front of a sequence
encoding HA-tag at the C-terminus of ErbB4 CYT2 80 kDa
fragment [20]. Flag-tagged syndecan-4 expression con-
struct in pcDNA3.1 Neo vector (Promega, USA) was gen-
erated by trimming the flag-peptide encoding sequence to
the 3'-terminus of syndecan-4 cDNA derived from MCF-7
cells.
Cell culture
Generation and maintenance of the MCF-7 human breast
cancer cells expressing human ErbB4 JM-a CYT-2 has been
described previously [8]. T47D cells were maintained in
RPMI-1640 medium supplemented with 10 FCS and
glutamine. For immunoblot analysis cells were grown to
40–50% confluency on 6-well tissue culture plates. For
confocal microscopy, cells were grown on coverslips in
flat-bottomed 24-well tissue culture plates. Transfections
were done by using Fugene-6 transfection reagent (Roche,
Switzerland).
Preparation and analysis of cell lysates
Cells grown to 70% confluency on 6-well tissue culture
plates were washed twice with PBS prior to treatments.
Incubations with enzymes and control treatments were
performed at +37°C for 30 min in PBS supplemented
with 10 μM calcium acetate and 10 mM glucose. Hepari-
tinase and chondroitinase (Seikagaku, Japan) were used at
0.01 U/ml. After incubation cells were lysed as described
previously [8] in the presence of TACE inhibitor 2 mM
1,10 orto-phenanthroline (Sigma-Aldrich, USA) [21]. For
immunoprecipitation the NaCl concentration of the
lysates were adjusted to 150 mM. The precipitations and
immunoblots were performed as previously described [8].
Measurement of TACE activity
Recombinant human TACE and TACE substrate peptide
(Fluorescent substrate peptide III) were purchased from
R&D Systems (USA). The amount of generated fluores-
cence was measured according to manufacturer's instruc-
tions after 60 min incubation at +37°C in the presence or
absence of increasing concentrations of bovine lung
heparin (Sigma-Aldrich, USA) or bovine kidney HS
(Sigma-Aldrich, USA). TACE activity on living MCF-7 cells
was measured after cells were grown to 80% confluency
on flat-bottomed 96-well plates. Cells were incubated for
30 min in PBS containing 10 mM glucose in the presence
or absence of 0.001 U/ml heparitinase or chondroitinase
(Seikagaku, Japan). After incubation, cells were washed
and the generation of fluorescent end product was fol-
lowed at 5 min intervals. The enzyme assay buffer was
supplemented with 0.2 mM phenylmethyl sulphonium
fluoride and 5 mM EDTA.
Confocal microscopy
Cells grown on coverslips were fixed and permeabilized
with ice-cold methanol. Primary antibodies were used as
following dilutions: HFR-1 monoclonal mouse anti-
ErbB4 intracellular fragment (Neomarkers, USA) at 1:50;
monoclonal rat anti-hemagglutinin 12CA5 epitope and
monoclonal mouse anti-myc 9E10 epitope at 1:100
(Zymed, USA). Secondary antibodies were diluted in 10%
FBS-PBS as follows: Alexa-568 goat anti-rat at 1:400;
Alexa-488 goat anti-mouse at 1:400 (Molecular Probes,
USA). Coverslips were embedded on Vecta Shield Hard
Set mounting solution containing DAPI. Samples were
analyzed with Zeiss LSM-510 Meta confocal microscope.
Results and Discussion
Cleavage of ErbB4 receptor to soluble ectodomain and
membrane-bound 80 kDa fragment can be induced byBMC Cell Biology 2009, 10:5 http://www.biomedcentral.com/1471-2121/10/5
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receptor-ligand binding and phorbol myristyl acetate
(PMA) [22] and the cleavage is dependent on TACE activ-
ity [6,8]. The quantity of ErbB4 JM-a CYT-2 80 kDa frag-
ment upon treatment of MCF-7 cells with heparitinase
was increased to extent comparable to control treatment
with PMA (Fig. 1A). No increase in the amount of ErbB4
80 kDa fragment could be detected after degradation of
cell surface HS with the presence of TAPI-0, a potent
inhibitor for TACE [8]. To ascertain that presence of
TACE-cleavable ErbB4 juxtamembrane domain is
A) The effects of heparitinase and PMA can be reverted by adding 40 μM TAPI-0 to the incubation medium Figure 1
A) The effects of heparitinase and PMA can be reverted by adding 40 μM TAPI-0 to the incubation medium. 
MCF-7 cells were treated for 30 minutes and Triton-X100 soluble lysates containing 40 μg protein were subjected to immuno-
blot. The position of full length ErbB4 protein and ErbB4 80 kDa fragment as detected by the polyclonal sc-283 anti ErbB4 anti-
body are indicated by arrows. B) The effect of heparitinase is specific for TACE-cleavable (JM-a) ErbB4 isoform. MCF-7 cells 
were transiently transfected with ErbB4 JM-a CYT2HA or JM-b CYT2HA gene construct. Lysates were subjected to immuno-
blot with HA-specific monoclonal antibody. C) The effect of heparitinase treatment could be demonstrated in T47D cells 
treated similarly to MCF-7 cells. D) Degradation of chondroitin sulfate did not increase the formation of ErbB4 80 kDa frag-
ment in T47D cells. E) Heat inactivated incubation medium from heparitinase treatment of T47D cells had only small effect on 
ErbB4 80 kDa fragment formation. The intensity of the ErbB4 80 kDa fragment staining as indicated in C and D was quantified 
with ImageJ software vs. 1.38 (NIH, USA). Beta-actin was used as load control (not shown). Abbreviations: Htase, heparitinase; 
Ctase, chondroitinase, PMA, phorbol myristyl acetate. Ht med. heat inactivated heparitinase incubation medium. The images 
are representative of at least three independent analyses.
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required for the cleavage of the receptor induced by HS
removal, MCF-7 cells were transiently transfected with
carboxy-terminally hemagglutinin-tagged ErbB4 JM-a
CYT-2 or JM-b CYT-2 receptor isoform. The carboxytermi-
nal HA-tag has recently been shown not to affect the
ErbB4 receptor cleavage [23]. As expected, no 80 kDa HA-
immunoreactive protein was present in JM-b CYT2HA
expressing cells (Fig. 1B). The enhancement of ErbB4 80
kDa fragment formation could be demonstrated also in
the context of endogenously expressed ErbB4 in T47D
human breast cancer cells (Fig. 1C). Degradation of chon-
droitin sulfate did not impose similar effect on ErbB4 80
kDa fragment formation as heparitinase (Fig. 1D). Degra-
dation of cell surface HS can potentially release growth
factors or induce their processing form membrane bound
precursors which in turn may trigger growth factor recep-
tor processing. Members of the epidermal growth factor
family are generally heat-stabile [24] whereas heparitinase
is readily inactivated in temperatures over 52°C [25].
Incubation supernatant from heparitinase treatment of
T47D cells was heat inactivated 10 minutes at 65 °C and
used to treat T47D cells. Only minor effect on ErbB4 80
kDa fragment formation could be demonstrated with
heat-inactivated supernatant compared to heparitinase
treatment (Fig. 1E). This indicated that the effect of hepar-
itinase treatment appears to be mainly due to the removal
of HS per se. However, growth factor release induced
receptor processing may simultaneously happen in
smaller extent.
Confocal immunofluorescence microscopy (Fig. 2)
revealed that in untreated cells, the ErbB4 immunoreactiv-
ity was mostly detected at the plasma membrane with
some perinuclear immunoreactive granules present,
whereas heparitinase treatment increased the presence of
perinuclear ErbB4 C-terminus-specific granules in MCF-7
cells.
HS may mediate its effect on ErbB4 cleavage by interac-
tions between polysaccharide and TACE. If degradation of
Confocal microscopy illustration of samples of MCF-7 cells A-C) without treatment; D-F) treated 30 minutes with heparitinase  (in figure F a group of three cells), Cells were stained with ErbB4 carboxy-terminus specific HFR-1 antibody Figure 2
Confocal microscopy illustration of samples of MCF-7 cells A-C) without treatment; D-F) treated 30 minutes 
with heparitinase (in figure F a group of three cells), Cells were stained with ErbB4 carboxy-terminus specific 
HFR-1 antibody. Accumulation of immunoreactive perinuclear granules is indicated by arrows. G) Activity of Heparitinase 
was controlled by simultaneous Western analysis of ErbB4 cleavage from parallel samples.
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HS leads to elevated TACE-like activity, it should be possi-
ble to inhibit it with exogeneous heparin or HS. Indeed,
the enhanced formation of ErbB4 80 kDa fragment by
heparitinase could be inhibited with the presence of 1 μg/
ml heparin (Fig. 3A). Figure 3B shows that, exogenous
heparin had no effect on ErbB4 80 kDa fragment forma-
tion in untreated MCF-7 cells. The capability of heparin
and HS to inhibit TACE activity was further demonstrated
by using recombinant TACE and a TACE-specific peptide
substrate as shown in Figure 3C. Further, we evaluated
heparin dependent inhibition of TACE activity on living
cells. TACE substrate peptide cleavage was accelerated
Exogeneous heparin or HS inhibit heparitinase-induced ErbB4 80 kDa fragment formation Figure 3
Exogeneous heparin or HS inhibit heparitinase-induced ErbB4 80 kDa fragment formation. A) Small concentra-
tions of heparin slightly enhance the heparitinase-induced ErbB4 80 kDa fragment formation, whereas 1 μg/ml heparin and 
higher concentrations inhibit ErbB4 80 kDa fragment formation as indicated in lysates of T47D cells. B) Incubation with 
increasing concentrations of bovine lung heparin only did not have marked effect on cells. N. s., non-specific staining in A and B. 
C) Both heparin and heparan sulfate inhibited activity of recombinant TACE at high concentrations but displayed some 
enhancement of enzyme activity at low concentrations D) Heparitinase treatment of living MCF-7 cells enhanced cleavage of 
fluorescent TACE substrate peptide (p = 6 × 10-11) and the effect of heparitinase could be largely reverted by adding 40 μM 
TAPI-0 to the incubation medium (p = 10-5). The p-values were calculated with two-tailed pairwise Student's test comparing all 
time points. The enzyme activity analysis was performed three times with similar results. The data shown represents results 
from a single assay.
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when MCF-7 cells were treated with heparitinase prior
addition of substrate peptide (Figure 3D). Moreover, the
effect of heparitinase could be largely reverted by addition
of TACE inhibitor TAPI-0 to the enzyme assay buffer.
Of the members of the syndecan proteoglycan family we
could demonstrate co-immunoprecipitation and colocal-
ization of syndecan-4 with TACE. Figure 4A shows that rat
anti-HA antibody precipitates both the TACE-HA and syn-
decan-4-flag proteins from lysates of MCF-7 cells tran-
siently transfected to express the tagged protein
constructs. Further, the co-immunoprecipitation of syn-
decan-4 could be abolished by heparitinase treatment of
the cells prior lysis. Confocal microscopy revealed that in
untreated cells TACE is mostly located at the cell surface
and the Golgi compartment. Also, syndecan-4 is mostly
present at cell surface, and the cell surface immunoreactiv-
ity is located at the same structures as TACE-HA (Figure
4B). When cells were treated with heparitinase, syndecan-
4 core protein translocated to intracellular vesicles.
Two mechanisms for HS-mediated regulation of TACE-
activity can be postulated. HS may hinder TACE-mediated
ErbB4 cleavage by forming steric barriers between the
enzyme and its substrate cleavage site or directly inhibit-
ing TACE activity with interactions between the enzyme
and HS side chains. As soluble heparin and HS inhibited
cleavage of fluorescent substrate peptide by recombinant
TACE enzyme, the presence of the latter mechanism is
suggested. This is further supported by the fact that exog-
enous heparin and HS hindered the HS degradation
induced ErbB4 cleavage.
Conclusion
In this communication removal of cell surface HS was
shown to increase TACE activity and TACE-dependent for-
mation of ErbB4 80 kDa intracellular domain. The high
HS degrading activity reportedly present in tumor tissues
[13-17] thus probably favors TACE-activity which may
lead to elevated processing of ErbB4 and promotion of
cell survival. Analogous mechanisms may be active also in
inflammed tissue and may also concern other proteolyti-
cally processed transmembrane proteins.
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